Merck KGaA (OTC:MKGAF) is seeking worldwide regulatory approval for its CSF-1R inhibitor pimicotinib following robust Phase III results in tenosynovial giant cell tumour (TGCT). The MANEUVER trial, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback